A leading specialized clinical pathology laboratory offering a wide range of high added medical value tests, covering a wide range of specialties. The catalog contains over 1,300 tests and is constantly being enriched.
Dive into the heart of innovation:
Franck Hermet, Technical Platform Director
The largest specialized clinical pathology laboratory in France and Europe and the leading laboratory for the analysis of samples from French overseas territories
Opened in 2024, Frépillon covers an area of 57,000m2 to the north of Paris. Its 17,000m2 technical platform makes it the largest laboratory in Europe. It is also the most modern and innovative, with a single 120-meter long automated chain connecting around thirty automated analytical machines and some sixty pre- and post-analytical units (centrifuges, sorters, etc.). The site also echoes the wider challenges facing society and has established an ambitious environmental strategy with the recent award of the BREEAM certification and with a view to obtaining the Biodiversity Progress label.
Tests are carried out on a cutting-edge technological platform, combining old techniques that are still the benchmark today with the latest innovations in the sector.
This enables Cerba to offer the most appropriate and highest quality tests, with highly competitive turnaround times and a high level of traceability.
A single, high-capacity platform, combined with our logistical, pre-analytical and analytical expertise, enables excellent human and material reactivity for high-volume requirements and optimized management of emergency requests. Since 2015, we have had a dedicated service for colorectal cancer screening in France, enabling us to process up to 80,000 samples per week during national screening campaigns.
Cerba's high level of medical expertise is based on a team of medical biologists and scientists who are experts in their fields and recognized by their peers. A client-focused approach means they are on hand to assist and advise healthcare professionals in choosing the best tests and interpreting results to improve patient care.
As a healthcare player, Cerba has always followed a mission of working for the common good, alongside public health players. It participates in numerous epidemiology surveillance networks, scientific societies and public-private partnerships. The new platform, opened in 2024, is configured for fast mobilization in the event of a pandemic, with two P3 laboratories dedicated to the risks of emerging and epidemic diseases and/or suspect samples.
